Canadian research company Neonmind Biosciences recently filed provisional patents for using psychedelic substances psilocybin and lysergic acid diethylamide (“LSD”) as medical treatments for for compulsive eating disorder, obesity, and a range of related illnesses. The provisional patents cover a guided therapeutic protocol to be used prior to, during, and after the patient’s psychedelic experiences.
The use of psychedelics is often tied to short-term appetite suppression anecdotally, but Neonmind’s treatment is designed to help patients gain insights from their psychedelic experiences that can be integrated into their daily lives. Treatment can “include an exploration of unresolved issues in the patient’s life that are embedded in his or her subconscious, including discussions or examinations of pain. It may also include building self-esteem, the patient taking responsibility for his or her own condition, self empowerment, and acknowledging or releasing any unhealthy self defence mechanism of overeating.”
In addition to providing weight loss and related benefits such as treatment for diabetes, high-blood pressure, and cardiovascular disease, Neonmind hopes to use their psychedelic formulations to treat a variety of health conditions including multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma, and certain forms of cancer.
Neonmind expects to begin an initial preclinical trial in the fall of 2020 through Translational Life Sciences Inc., a research organization in which Neonmind holds an 18% stake. Following the completion of the preclinical trials, phase 2 human clinical trials could begin in 2021. Research will have to be approved by Health Canada before the preclinical trials can begin.